Lenvatinib HCC Data Published as FDA Considers Approval

February 20, 2018 – Lenvatinib was noninferior for overall survival (OS) while improving progression-free survival (PFS) compared with sorafenib for the frontline treatment of patients with unresectable hepatocellular carcinoma (HCC), according to findings from the phase III REFLECT trial now published online in the Lancet. Based on these pivotal findings, the FDA is considering an application for lenvatinib in the first-line HCC setting. In the phase III multicenter, open- … (leggi tutto)